Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Combination With Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04956302Phase 1Terminated
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of panobinostat in multiple myeloma (MM). Primary endpoints: Recommended phase 2 dose at 28 days and Incidence of adverse events at 3 years. Started Sep 2021; status: terminated.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04956302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956302.